Table 2.
Demographic and clinical characteristics of 557 patients with myeloma included in the study
| Patients | ||
|---|---|---|
| Variable | n | % |
| a) Socio-demographic details | ||
| Age: Mean (SD, range) | 68.41 | (SD 10.4; 34–92) |
| Gender | ||
| Men | 341 | 61.2 |
| Women | 209 | 37.5 |
| Missing | 7 | 1.3 |
| Ethnicity | ||
| White British/Irish/Other white background | 513 | 92.1 |
| Black African or Black Caribbean | 19 | 3.4 |
| Mixed ethnic background | 4 | 0.7 |
| Other | 14 | 2.5 |
| Missing | 7 | 1.3 |
| Marital status | ||
| Single | 44 | 7.9 |
| Married | 400 | 71.8 |
| Divorced or separated | 36 | 6.5 |
| Widowed | 68 | 12.2 |
| Missing | 9 | 1.6 |
| Occupational status | ||
| Working or student | 82 | 14.7 |
| Not working or retired | 467 | 83.9 |
| Missing | 8 | 1.4 |
| b) Disease factors | ||
| Current phase of illness | ||
| Newly diagnosed | 102 | 18.3 |
| Treatment-free interval/stable disease | 266 | 47.8 |
| Relapsed/progressive/palliative stage | 182 | 32.7 |
| ISS stage at diagnosis | ||
| I | 154 | 27.6 |
| II | 109 | 19.6 |
| III | 116 | 20.8 |
| Missing | 178 | 32.0 |
| Time since diagnosis in years: Mean (SD) | 3.53 | (3.4) |
| Median, range (in years) | 2.5 | (0.08–23.6) |
| Immunoglobulin type | ||
| IgG | 314 | 56.4 |
| IgA | 118 | 21.2 |
| Kappa or lambda light chain | 95 | 17.1 |
| Other | 15 | 2.7 |
| Missing | 15 | 2.7 |
| ECOG performance status | ||
| 0 Fully active | 188 | 33.8 |
| 1 Restricted | 222 | 39.9 |
| 2 Unable to work | 87 | 15.6 |
| 3 or 4 – Limited selfcare/confined | 50 | 9.0 |
| Missing | 10 | 1.8 |
| Total number of symptoms on MyPOS | ||
| 0 | 5 | 0.9 |
| 1–5 | 175 | 31.4 |
| 6–8 | 168 | 30.2 |
| 9–15 | 205 | 36.8 |
| Missing | 4 | 0.7 |
| d) Treatment factors | ||
| Lines of treatment: Median (range) | 1 | (0–6) |
| Previously untreated | 30 | 5.4 |
| 1 line received | 249 | 44.7 |
| 2 lines received | 155 | 27.8 |
| 3 or more lines received | 123 | 22.1 |
| Currently on treatment | 292 | 52 |
| Active chemotherapy | 213 | – |
| Undergoing autologous stem cell transplant | 5 | – |
| Maintenance therapy | 74 | – |
| Current MM treatment | ||
| Bortezomib | 59 | 27.6 |
| Lenalidomide | 89 | 41.9 |
| Thalidomide/Pomalidomide | 56 | 26.5 |
| Alkalyting agent | 111 | 51.9 |
| Other | 2 | 0.9 |
| Combination chemotherapy | 110 | 51.4 |
| Intensity of treatments received | ||
| None | 54 | 9.7 |
| Chemotherapy only | 303 | 54.4 |
| Chemotherapy and stem cell transplant | 161 | 28.9 |
| More than one transplant | 32 | 5.7 |
| Missing | 7 | 1.3 |
Abbreviations: ECOG Eastern Cooperative Oncology Group performance status, ISS International staging system classification of myeloma [36], MyPOS: Myeloma Patient Outcome Scale, SD Standard deviation